Bridged Tricyclic GABA Derivatives for Lower-CNS α2δ Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing α2δ ligands like gabapentin and pregabalin exhibit limited efficacy and CNS adverse effects in managing neuropathic pain, necessitating the development of next-generation compounds with improved therapeutic performance and safety profiles.

Innovation Solution

Development of bridged tricyclic GABA derivatives that act as ligands targeting the α2δ subunit of voltage-gated calcium channels, offering enhanced therapeutic efficacy and safety for treating neuropathic pain.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing α2δ ligands like gabapentin and pregabalin are used, then therapeutic efficacy is achieved, but CNS adverse effects occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidCNS adverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical structure of existing α2δ ligands by changing molecular parameters - specifically incorporating bridged tricyclic GABA derivatives with modified molecular weight, lipophilicity, and structural configuration. These parameter changes result in compounds that maintain therapeutic efficacy while reducing CNS adverse effects such as dizziness and somnolence.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If existing α2δ ligands are used, then pain management is achieved, but efficacy is limited

Engineering Contradiction:

Improvepain management efficacyVSAvoidtherapeutic performance

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent creates composite molecular structures by combining bridged tricyclic frameworks with GABA derivative moieties. This composite approach yields compounds that exhibit enhanced binding affinity to α2δ subunits and improved pharmacological profiles, achieving better pain management efficacy compared to existing single-structure ligands.

Inventive Principle:

Principle #40Composite materials

3Reliability

If gabapentin and pregabalin are used, then neuropathic pain is managed, but safety profile is compromised

Engineering Contradiction:

Improveneuropathic pain managementVSAvoidsafety profile

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and removes problematic structural elements from existing α2δ ligands that cause CNS adverse effects. By taking out specific molecular features responsible for harmful effects and retaining only the essential binding moieties, the invention creates safer compounds with improved safety profiles while maintaining neuropathic pain management capabilities.

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS20260034098A1Bridged tricyclic GABA derivatives as calcium channel modulators, methods of making and methods of using thereof

Publication Date: 2026.02.05 YICHANG HUMANWELL PHARMA CO LTD

AI summary

This invention discloses bridged tricyclic γ-aminobutyric acid (GABA) derivatives targeting the α2δ subunit of voltage-gated calcium channels. These compounds exhibit enhanced binding affinity and improved pharmacological profiles. They aim to overcome limitations of current α2δ ligands like gabapentin and pregabalin. The new derivatives show potential for treating neuropathic pain, epilepsy, and related disorders.